| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05a203d85ee01909eaf728dc16f0f6cb |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545 |
| filingDate |
2012-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_446c2b11caeaf50e179b2bc8b6593d75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a497cab94d8af3c9fe01bd63fe83339 |
| publicationDate |
2014-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-103841972-A |
| titleOfInvention |
Crizotinib for the treatment of cancer |
| abstract |
The present invention relates to the use of ROS kinase inhibitors for the treatment of abnormal cell growth in mammals. In particular, the invention provides methods of treating a mammal suffering from cancer mediated by at least one genetically altered ROS. In particular, the invention provides methods of treating a mammal suffering from cancer mediated by at least one genetically altered ROS by administering crizotinib. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021196655-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113493437-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113493437-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111518769-A |
| priorityDate |
2011-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |